Abstract
p53 is one of the most important tumor suppressor genes that is frequently mutated in human cancers. Generally, p53 functions as a transcription factor that is stabilized and activated by various genotoxic and cellular stress signals, such as DNA damage, hypoxia, oncogene activation and nutrient deprivation, consequently leading to cell cycle arrest, apoptosis, senescence and metabolic adaptation. p53 not only becomes functionally deficient in most cancers, but not infrequently mutant p53 also acquires dominant negative activity and oncogenic properties. p53 has remained an attractive target for cancer therapy. Strategies targeting p53 have been developed including gene therapy to restore p53 function, inhibition of p53-MDM2 interaction, restoration of mutant p53 to wild-type p53, targeting p53 family proteins, eliminating mutant p53, as well as p53-based vaccines. Some of these p53-targeted therapies have entered clinical trials. We discuss the therapeutic potential of p53, with particular focus on the therapeutic strategies to rescue p53 inactivation in human cancers. In addition, we discuss the challenges of p53-targeted therapy and new opportunities for the future.
Keywords: Tumor suppressor, p53, mutant p53, p53-targeted therapy, restoration of p53, MDM2, p53 family protein.
Current Drug Targets
Title:Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Volume: 15 Issue: 1
Author(s): Bo Hong, A. Pieter J. van den Heuvel, Varun V. Prabhu, Shengliang Zhang and Wafik S. El-Deiry
Affiliation:
Keywords: Tumor suppressor, p53, mutant p53, p53-targeted therapy, restoration of p53, MDM2, p53 family protein.
Abstract: p53 is one of the most important tumor suppressor genes that is frequently mutated in human cancers. Generally, p53 functions as a transcription factor that is stabilized and activated by various genotoxic and cellular stress signals, such as DNA damage, hypoxia, oncogene activation and nutrient deprivation, consequently leading to cell cycle arrest, apoptosis, senescence and metabolic adaptation. p53 not only becomes functionally deficient in most cancers, but not infrequently mutant p53 also acquires dominant negative activity and oncogenic properties. p53 has remained an attractive target for cancer therapy. Strategies targeting p53 have been developed including gene therapy to restore p53 function, inhibition of p53-MDM2 interaction, restoration of mutant p53 to wild-type p53, targeting p53 family proteins, eliminating mutant p53, as well as p53-based vaccines. Some of these p53-targeted therapies have entered clinical trials. We discuss the therapeutic potential of p53, with particular focus on the therapeutic strategies to rescue p53 inactivation in human cancers. In addition, we discuss the challenges of p53-targeted therapy and new opportunities for the future.
Export Options
About this article
Cite this article as:
Hong Bo, Heuvel Pieter J. van den A., Prabhu V. Varun, Zhang Shengliang and El-Deiry S. Wafik, Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114666140106101412
DOI https://dx.doi.org/10.2174/1389450114666140106101412 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tuber Lectins with Potentially Exploitable Bioactivities
Current Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Carvacrol Exhibits Chemopreventive Potential against Cervical Cancer Cells via Caspase-Dependent Apoptosis and Abrogation of Cell Cycle Progression
Anti-Cancer Agents in Medicinal Chemistry Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Leaf Extract of <i>Nerium oleander</i> L. Inhibits Cell Proliferation, Migration and Arrest of Cell Cycle at G2/M Phase in HeLa Cervical Cancer Cell
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review on Combretastatin Analogues as Tubulin Binding Agents
Current Organic Chemistry An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Applications of the Rare Earth Elements in Cancer Imaging and Therapy
Current Nanoscience Advances in Targeted Gene Delivery
Current Drug Delivery Viral and Non-Viral Methods to Genetically Modify Dendritic Cells
Current Gene Therapy Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking Library
Combinatorial Chemistry & High Throughput Screening Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Dysregulation of lncRNA and circRNA Expression in Mouse Testes after Exposure to Triptolide
Current Drug Metabolism Proceedings of the 1<sup>st</sup> Puerto Rico Biobanking Workshop
Reviews on Recent Clinical Trials